ANTI-ANGINAL GUIDELINES NEED NOT AGREE WITH EC DRAFT, ADVISORY COMMITTEE SAYS; RECOMMENDS WORKSHOP TO DETERMINE EARLY STAGE ISSUES IN DRUG DEVELOPMENT
FDA should convene a workshop to discuss issues of dose-response and selection in clinical development, FDA Cardiovascular & Renal Drugs Advisory Committee temporary member Craig Pratt, MD, Methodist Hospital (Houston), suggested during the panel's discussion of anti-anginal drug development guidelines Feb. 24.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth